Literature DB >> 29891534

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.

Marion Lenglet1,2,3, Florence Robriquet2,3, Klaus Schwarz4,5, Carme Camps6,7, Anne Couturier8, David Hoogewijs9, Alexandre Buffet10,11,12, Samantha J L Knight6,7, Sophie Gad1,13, Sophie Couvé1,13, Franck Chesnel8, Mathilde Pacault2,14, Pierre Lindenbaum3, Sylvie Job15, Solenne Dumont2, Thomas Besnard3,14, Marine Cornec3, Helene Dreau16, Melissa Pentony6,7, Erika Kvikstad6,7, Sophie Deveaux17,18,19,20, Nelly Burnichon10,11,12,18,19,21, Sophie Ferlicot17,22, Mathias Vilaine2, Jean-Michaël Mazzella10,11,12,18,19,21, Fabrice Airaud14, Céline Garrec14, Laurence Heidet23, Sabine Irtan24, Elpis Mantadakis25, Karim Bouchireb23, Klaus-Michael Debatin26, Richard Redon3, Stéphane Bezieau3,14, Brigitte Bressac-de Paillerets13,27, Bin Tean Teh28, François Girodon29,30,31, Maria-Luigia Randi32, Maria Caterina Putti33, Vincent Bours34, Richard Van Wijk35, Joachim R Göthert36, Antonis Kattamis37, Nicolas Janin38, Celeste Bento39, Jenny C Taylor6,7, Yannick Arlot-Bonnemains8, Stéphane Richard1,13,17,18,19,20, Anne-Paule Gimenez-Roqueplo10,11,12,18,19,21, Holger Cario26, Betty Gardie1,2,3,31.   

Abstract

Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with VHL disease, which is characterized by the development of highly vascularized tumors. Here, we identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. More importantly, we identify mutations in E1' in 7 families with erythrocytosis (1 homozygous case and 6 compound-heterozygous cases with a mutation in E1' in addition to a mutation in VHL coding sequences) and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, we show that the mutations induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In addition, we demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease. In all the studied cases, the mutations differentially affected splicing, correlating with phenotype severity. This study demonstrates that cryptic exon retention and exon skipping are new VHL alterations and reveals a novel complex splicing regulation of the VHL gene. These findings open new avenues for diagnosis and research regarding the VHL-related hypoxia-signaling pathway.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29891534     DOI: 10.1182/blood-2018-03-838235

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease.

Authors:  Shahida K Flores; Ziming Cheng; Angela M Jasper; Keiko Natori; Takahiro Okamoto; Akiyo Tanabe; Koro Gotoh; Hirotaka Shibata; Akihiro Sakurai; Takuya Nakai; Xiaojing Wang; Magnus Zethoven; Shiva Balachander; Yuichi Aita; William Young; Siyuan Zheng; Kazuhiro Takekoshi; Eijiro Nakamura; Richard W Tothill; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  J Clin Endocrinol Metab       Date:  2019-04-04       Impact factor: 5.958

2.  Diagnostic workflow for hereditary erythrocytosis and thrombocytosis.

Authors:  Mary Frances McMullin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

3.  A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?

Authors:  Fatemeh Azimi; Ali Aghajani; Golnaz Khakpour; Samira Chaibakhsh
Journal:  Mol Genet Genomics       Date:  2022-08-25       Impact factor: 2.980

4.  Commentary: Von Hippel-Lindau disease: A clinical and scientific review.

Authors:  Malak Abedalthagafi
Journal:  Eur J Hum Genet       Date:  2022-10-03       Impact factor: 5.351

Review 5.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

Review 6.  Erythrocytosis: genes and pathways involved in disease development.

Authors:  Jernej Gašperšič; Aleša Kristan; Tanja Kunej; Irena Preložnik Zupan; Nataša Debeljak
Journal:  Blood Transfus       Date:  2020-12-16       Impact factor: 3.443

7.  Germline mutations in the new E1' cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma.

Authors:  Bruna Calsina; Shahida Flores; Sophie Giraud; Marion Lenglet; Alexandre Buffet; Pauline Romanet; Elisa Deflorenne; Javier Aller; Isabelle Bourdeau; Brigitte Bressac-de Paillerets; María Calatayud; Caroline Dehais; Erwan De Mones Del Pujol; Atanaska Elenkova; Philippe Herman; Peter Kamenický; Sophie Lejeune; Jean Louis Sadoul; Anne Barlier; Stephane Richard; Judith Favier; Nelly Burnichon; Betty Gardie; Patricia L Dahia; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo
Journal:  J Med Genet       Date:  2020-01-29       Impact factor: 6.318

8.  Reinterpretation, reclassification, and its downstream effects: challenges for clinical laboratory geneticists.

Authors:  Julia El Mecky; Lennart Johansson; Mirjam Plantinga; Angela Fenwick; Anneke Lucassen; Trijnie Dijkhuizen; Annemieke van der Hout; Kate Lyle; Irene van Langen
Journal:  BMC Med Genomics       Date:  2019-11-29       Impact factor: 3.063

9.  Identification of Variants Associated With Rare Hematological Disorder Erythrocytosis Using Targeted Next-Generation Sequencing Analysis.

Authors:  Aleša Kristan; Tadej Pajič; Aleš Maver; Tadeja Režen; Tanja Kunej; Rok Količ; Andrej Vuga; Martina Fink; Špela Žula; Helena Podgornik; Saša Anžej Doma; Irena Preložnik Zupan; Damjana Rozman; Nataša Debeljak
Journal:  Front Genet       Date:  2021-07-19       Impact factor: 4.599

Review 10.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.